PH HEALTH
GenericsPH HEALTH is a generic drug manufacturer focused on Cardiovascular, Neurology, Infectious Disease. Key products include MICAFUNGIN.
PH HEALTH's Key Drugs
PH HEALTH's core commercial portfolio centers on OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, ADRENALIN, OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.
Major Depressive Disorder
Anaphylaxis
Hypertension
Helicobacter pylori Infection
Benign Prostatic Hyperplasia
PH HEALTH's Recent FDA Approvals
New NDA/BLA approvals for PH HEALTH over the last two years — novel drugs only, excluding generics and label supplements.
PH HEALTH's Therapeutic Areas
PH HEALTH's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 7 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PH HEALTH's Top Competitors
PH HEALTH's closest competitors by therapeutic-area and drug-target overlap include Merck, Novo Nordisk, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PH HEALTH Pipeline Snapshot
Active clinical trials for PH HEALTH across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • OLANZAPINE AND FLUOXETINE HYDROCHLORIDE leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (7)
Discontinued (12)
Company Info
- First Approval
- 1947-07-28
- Latest
- 2026-10-19
- Applications
- 201